JP2021535163A5 - - Google Patents

Info

Publication number
JP2021535163A5
JP2021535163A5 JP2021511544A JP2021511544A JP2021535163A5 JP 2021535163 A5 JP2021535163 A5 JP 2021535163A5 JP 2021511544 A JP2021511544 A JP 2021511544A JP 2021511544 A JP2021511544 A JP 2021511544A JP 2021535163 A5 JP2021535163 A5 JP 2021535163A5
Authority
JP
Japan
Prior art keywords
composition
composition according
taurinamide
taurartum
once
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021511544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535163A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/048592 external-priority patent/WO2020047113A1/en
Publication of JP2021535163A publication Critical patent/JP2021535163A/ja
Publication of JP2021535163A5 publication Critical patent/JP2021535163A5/ja
Priority to JP2024154822A priority Critical patent/JP2024170590A/ja
Pending legal-status Critical Current

Links

JP2021511544A 2018-08-28 2019-08-28 タウロリジン加水分解産物による神経芽細胞腫治療 Pending JP2021535163A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024154822A JP2024170590A (ja) 2018-08-28 2024-09-09 タウロリジン加水分解産物による神経芽細胞腫治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862723618P 2018-08-28 2018-08-28
US62/723,618 2018-08-28
PCT/US2019/048592 WO2020047113A1 (en) 2018-08-28 2019-08-28 Neuroblastoma treatment with taurolidine hydrolysis products

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024154822A Division JP2024170590A (ja) 2018-08-28 2024-09-09 タウロリジン加水分解産物による神経芽細胞腫治療

Publications (2)

Publication Number Publication Date
JP2021535163A JP2021535163A (ja) 2021-12-16
JP2021535163A5 true JP2021535163A5 (cg-RX-API-DMAC7.html) 2022-08-30

Family

ID=69645349

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021511544A Pending JP2021535163A (ja) 2018-08-28 2019-08-28 タウロリジン加水分解産物による神経芽細胞腫治療
JP2024154822A Pending JP2024170590A (ja) 2018-08-28 2024-09-09 タウロリジン加水分解産物による神経芽細胞腫治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024154822A Pending JP2024170590A (ja) 2018-08-28 2024-09-09 タウロリジン加水分解産物による神経芽細胞腫治療

Country Status (7)

Country Link
EP (1) EP3843746A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021535163A (cg-RX-API-DMAC7.html)
KR (1) KR20210050544A (cg-RX-API-DMAC7.html)
CN (1) CN113347976A (cg-RX-API-DMAC7.html)
AU (1) AU2019330954B2 (cg-RX-API-DMAC7.html)
CA (1) CA3111057A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020047113A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020047530A1 (en) * 2018-08-31 2020-03-05 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
US20220313702A1 (en) * 2019-05-22 2022-10-06 Geistlich Pharma Ag Oxathiazin compounds for inhibiting gapdh
CN116769723B (zh) * 2023-08-09 2023-11-03 山东省成体细胞产业技术研究院有限公司 一种gd2嵌合抗原受体修饰的t细胞及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602150A (en) * 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US20050096314A1 (en) * 2001-04-03 2005-05-05 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
EP1246617B1 (en) * 1999-12-06 2006-09-13 Rhode Island Hospital Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer
CN100519525C (zh) * 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
CA2363973C (en) * 2000-11-28 2009-03-10 Ed. Geistlich Sohne Ag Fur Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
ATE354380T1 (de) * 2003-02-03 2007-03-15 Polaschegg Hans-Dietrich Dr Te Zusammensetzung zur prävention von infektionen durch subkutane prothesen
JP2007537200A (ja) * 2004-05-14 2007-12-20 ハンス−ディートリヒ・ポラシェグ タウロリジン製剤及び投与:細菌マイクロフィルム形成に対する治療処置及び抗菌保護
EP1976531B1 (en) * 2006-01-06 2011-11-09 Ed. Geistlich Söhne AG für Chemische Industrie Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam
ES2614878T3 (es) * 2010-06-01 2017-06-02 Geistlich Pharma Ag Métodos y composiciones para terapia farmacéutica oral
CN104244949A (zh) * 2012-03-30 2014-12-24 诺华股份有限公司 用于治疗神经母细胞瘤、尤文氏肉瘤或横纹肌肉瘤的化合物
CA3010981C (en) * 2016-01-11 2024-09-17 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers

Similar Documents

Publication Publication Date Title
EP4631571A3 (en) Combination of dextromethorphan and bupropion for treating depression
FI3426285T3 (fi) Pegyloidun urikaasin formulaatioita ja annoksia
WO2003039436A3 (es) Composiciones farmaceuticas que contienen oxibutinina
JP2004508404A5 (cg-RX-API-DMAC7.html)
JP2002532392A5 (cg-RX-API-DMAC7.html)
ATE389389T1 (de) Mehrfach beschichete pharmazeutische dosierungsform
JP2020516646A5 (cg-RX-API-DMAC7.html)
EP4034156A1 (en) Combination therapy with cgrp antagonists
KR20140025314A (ko) 복합 조성물
US20030008875A1 (en) Use of regularly scheduled high dose intravenous methotrexate therapy, with interim administration of immunomodulatory agents, to treat multiple sclerosis and other diseases of the central nervous system
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
RU2009118962A (ru) Применение антагонистов il-1 для лечения подагры и псевдоподагры
FI4255563T3 (fi) 5’-o-fenyyliasetyyliuridiini ja terapeuttinen käyttö
RU2005126819A (ru) Усовершенствованное лечение опухолей
JP2008540364A5 (cg-RX-API-DMAC7.html)
JP2025148449A5 (cg-RX-API-DMAC7.html)
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2024170590A (ja) タウロリジン加水分解産物による神経芽細胞腫治療
JP2019506397A5 (cg-RX-API-DMAC7.html)
Galanello Iron chelation: new therapies
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
JP2019509309A5 (cg-RX-API-DMAC7.html)
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
WO2014176417A1 (en) Topical preparation for bypassing gi tract, delivery of therapeutics, and trans-epithelial drug delivery system
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis